Product development

SUBLIN BV, spin out from the pharma branch of NanoSERVE, aims to provide diabetic patients a disruptive alternative to their cumbersome insulin injections by developing orally-available insulin formulations.

SUBLIN BV, spin out from the pharma branch of NanoSERVE, aims to provide diabetic patients a disruptive alternative to their cumbersome insulin injections by developing orally-available insulin formulations. The strength of NanoSERVE’s proprietary technology is its tuneable, stable and safe-by-design formulation possibility. SUBLIN is in mid-preclinical phase with promising early large animal study findings. Our current focus is on optimizing the formulation to ensure optimal absorption, stability and safety. SUBLIN is expected to move forward towards clinical testing within five years.